Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986301 + nivolumab + ipilimumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Intratumoral, Intramuscular
01
Overview
BMS-986301 + nivolumab + ipilimumab is an investigational combination drug regimen composed of BMS-986301 (a next-generation cyclic dinucleotide analog and stimulator of interferon genes (STING) agonist), nivolumab (a PD-1 immune checkpoint inhibitor), and ipilimumab (a CTLA-4 immune checkpoint inhibitor). BMS-986301 is designed to activate the STING pathway, enhancing innate and adaptive immune responses against tumors. When combined with nivolumab and ipilimumab, it aims to potentiate T cell-mediated antitumor immunity, potentially overcoming resistance to prior checkpoint therapy. The combination is in Phase I clinical development for advanced solid tumors and other malignancies. Bristol Myers Squibb is the originator and developer of this investigational regimen[2][3][6][9].
- Other names
- BMS-986301 + nivolumab + ipilimumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TIM-1 (T-cell immunoglobulin and mucin domain-containing protein 1)STING (Stimulator of interferon genes protein)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on BMS-986301 + nivolumab + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986301 + nivolumab + ipilimumab.